News
-
Huge hydro setup
Friday | Dec 1 2017LISTED medicinal cannabis firm Cann Group has announced a $60 million capital raising in order to establish a 16,000 square metre facility to grow marijuana.
-
SIMPLER medication
Friday | Dec 1 2017THE Cognitive Decline Partnership Centre has announced a study focusing on quality use of medicines in the aged titled "Simplification of Medications Prescribed to Long Term Care Residents".
-
APP2018 program out
Friday | Dec 1 2017THE Pharmacy Guild of Australia has released the line-up for next year's Australian Pharmacy Professional Conference & Trade Exhibition (APP2018) which will take place at the Gold Coast Convention & Exhibition Centre.
-
Don’t sneeze at OTC relief
Friday | Dec 1 2017FOLLOWING mainstream media reports suggesting there is no role for oral antihistamines in the management of seasonal hayfever, the Australian Self Medication Industry (ASMI) has urged consumers who suffer from hayfever to discuss their symptoms with their doctor or pharmacist to ensure they receive the most appropriate treatment.
-
Symbion cuts trading terms
Friday | Dec 1 2017EBOS offshoot Symbion Health has reacted swiftly to the impact of AstraZeneca's decision to commence direct distribution, advising pharmacists of a reduction in trading terms effective today.
-
Travel Specials 30 Nov 17
Thursday | Nov 30 2017EXPLORE in Crystal luxury: Crystal Cruises has launched a new collection of Asia-Pacific voyages aboard its.
-
Dispensary Corner 30 Nov 17
Thursday | Nov 30 2017A Chinese barber is making headlines around the world after a video of his technique for shaving eyelids went viral on social media.
-
$2m for app study
Thursday | Nov 30 2017MENTAL health charity The Black Dog Institute has been granted $2.18 million to run a trial to evaluate whether mental health smartphone apps can help prevent depression in adolescents.
-
Healthpoint Digital has arrived
Thursday | Nov 30 2017IN-STORE displays have evolved, with the traditional 'Healthpoint' now relaunching as Healthpoint Digital - taking to the market a digital media platform that promotes professional service programs.
-
$5.3m raised for AD
Thursday | Nov 30 2017LISTED biotech company Actinogen Medical has raised $5.28m through a placement to investors, fully funding the completion of XanADu, Actinogen's Phase II trial of Xanamen in Alzheimer's disease (AD).
